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The heparan sulfate (HS) component of heparan sulfate proteoglycans 
(HSPGs) has been implicated in the initiation of several viral infections, 
including vaccinia virus (VACV). A cell infected with VACV releases two 
different forms of VACV, namely the mature virus (MV) released following the 
death of infected cells and which infects neighbouring cells, and the enveloped 
virus (EV) ejected from infected cells for long-range dissemination. The relative 
role of HS in the infectivity of the different forms of VACV is unclear. 
Furthermore, there is little known about the fine specificity of the VACV-HS 
interactions. Therefore, in order to develop HS based molecules that could 
potentially have antiviral properties against HS-dependent viral infection, VACV 
was used as a prototype virus to understand the structural and functional 
consequences of the interaction between VACV and HS. 
 
ELISA studies described in Chapter 3 were used to evaluate the specificity of 
the MV form of VACV for heparin, differentially sulfated HS, chondroitin sulfate 
(CS) A-D and hyaluronic acid (HA). Lack of appropriate EV specific antibodies 
meant that similar ELISA studies could not be performed for the EV form of 
VACV. Nevertheless, the MV form of VACV bound to immobilized heparin and 
highly sulfated HS (HShi) with high avidity, compared to lowly sulfated HS 
(HSlow). The MV particles also bound to CS A-D, however, very weakly. 
Furthermore, the ability of the MV rich Western Reserve (WR) strain of VACV to 
form plaques in vitro was affected by soluble heparin, WR plaque numbers 
being reduced 5-fold with an incremental increase in plaque size. The formation 
of plaques by the EV rich International Health Department-J (IHD-J) strain was 
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also affected in the presence of heparin, there being a 10-fold reduction in 
plaque numbers, an incremental increase in plaque size and the disappearance 
of the trademark ‘comet’ shaped plaques. These data suggest that HS 
recognition plays a significant role in both MV and EV infectivity, with this 
recognition being more important for EV infectivity. 
 
To better understand the interaction between heparin/HS and the two forms of 
VACV, green fluorescent protein (GFP) expressing recombinant strains of 
VACV were constructed, as described in Chapter 4. Subsequent inhibition of 
infectivity assays, performed using soluble glycosaminoglycans (GAGs), 
suggested that sulfated GAGs more easily inhibited EV infections than the MV 
infections, with heparin and HShi being highly potent inhibitors of infection. 
Furthermore, the ability of the EV form of VACV to establish an infection was 
significantly reduced in cells treated with the HS-degrading enzyme heparanase 
and in cells genetically deficient in HS production, compared to the MV form of 
VACV which appeared largely unaffected. These findings confirmed that 
recognition of cell surface HS is vital for EV infectivity but less important for the 
infectivity of the MV form of VACV. 
 
In Chapter 5, the ability of soluble heparin/HS molecules and HS mimetics to 
inhibit VACV infections was further investigated to identify structural features of 
these molecules that are responsible for their interaction with VACV particles. 
The study also aimed to determine whether HS-based molecules could be used 
as possible antivirals against VACV and potentially against other HS-dependent 
viral infections. It was observed that the 2-O-sulfate of uronic acid and the 6-O 
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and N-sulfate groups of glucosamine residues were important for VACV 
infectivity, with 6-O-sulfate being particularly crucial and EV infections being 
more dependent on these groups than MV infections. Furthermore, the length of 
heparin chains did not affect their ability to interact with and inhibit VACV 
infectivity. However, the linkages of different D-glucose-based HS mimetics had 
a profound effect on the ability of the sulfated molecule to inhibit VACV 
infections, with the order of potency being β(1g4) > α(1g6) > α(1g4) > 
β(1g3). Interestingly, however, a D-mannose-based sulfated oligosaccharide 
mixture (PI-88, Muparfostat) was identified as the only HS mimetic that was a 
more potent inhibitor of MV infections than of EV infections, in fact it was a 
stronger inhibitor of MV infections than unfractioned heparin (UFH). These data 
suggest that the EV and MV forms of VACV interact with different structural 
aspects of HS chains and that synthetic HS-based molecules could be 
designed with the ability to inhibit both EV and MV forms of VACV. 
 
In Chapter 6 studies are described that attempted to identify the proteins on the 
surface of the EV form of VACV that are responsible for the interaction of the 
VACV with cell surface HS. Thus, EV and MV outer membrane proteins were 
solubilised and identified by Western blotting using polyclonal anti-VACV 
antibodies. Four potential heparin-binding proteins were identified in the EV 
outer membrane extracts, being 150 kDa, 85 kDa, 60 kDa and 25 kDa proteins. 
The 150 kDa heparin binding protein was further analysed using 1D nanoLC 
ESI MS/MS and was found to be a poxvirus DNA directed RNA polymerase, 
with sequence similarity to the 65 kDa VACV F12 protein, a protein important in 
EV formation. Bioinformatic searches were also performed to determine 
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possible HS-binding motifs in VACV proteins and identified the 64 kDa VACV 
B4R protein and a 78 kDa RNA helicase as likely candidates. Overall, it was 
concluded that there are multiple HS binding proteins on the outer EV envelope 
and that it is likely that in many instances the heparin/HS binding site(s) of 
these EV proteins may not be composed of linear amino acid sequences. 
 
Since both MV and EV forms of VACV bind HS, in Chapter 7 experiments are 
described that examined the role of heparanase in VACV spread, it being 
predicted that heparanase may aid spread by releasing VACV from cell surface 
and extracellular matrix (ECM) HS. Wild type (WT) and heparanase deficient 
(HPSE -/-) mice were inoculated with the WR strain of VACV via intranasal (i.n.) 
and intramuscular (i.m.) routes to evaluate the spread of infection in the two 
groups of mice. The WR strain of VACV was inoculated via the i.n. route when 
there was a 24 hr delay in weight loss in the HPSE -/- mice compared to the WT 
mice. Furthermore, this delay in weight loss correlated with a delay in the onset 
of disease with there being a 24-48 hr delay in the spread of infection from the 
primary site of inoculation to distant organs like the ovaries. Similarly, when 
VACV was delivered by the i.m. route, there was a 24-48 hr delay in the 
infection of the ovaries, although there was a similar delay in infection of the 
spleen, despite there being no weight loss difference. Overall, the results 
suggest that VACV depends on host-derived heparanase to aid its spread. 
Since heparanase mediated degradation of HS aids the infiltration of leukocytes 
with antiviral activity into sites of infection, the results obtained from the current 
study are contrary to the prevailing immunological paradigm. 
 
	 xi	
In conclusion, VACV like several other viruses interacts with cell surface HS 
prior to infecting cells. Furthermore, VACV relies on host-derived heparanase to 
degrade cell surface and ECM HS to aid its spread. Thus, synthetic HS-based 
molecules could be designed that could inhibit EV and MV forms of VACV from 
infecting cells and may simultaneously act as heparanase inhibitors and 
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Oligo	name Length	(bp) Sequence	(5'-3') 
	 	 	 
MVAF	
Forward 25 GAGCAGCCTCGTCCACGTACACCGC 
	 	 	 
MVAF	
Reverse 31 GGTTCTTATAATTGTAACATCCTTCTCTTCC 


















































	 		 		 		 	
				





























the	absence	or	presence	of	soluble	HShi	and	HSlow.	Soluble	heparin	was	immobilised	in	assay	wells	as	a	BSA	conjugate	and	MV	binding	(106	PFU)	to	wells	determined	by	ELISA	using	polyclonal	rabbit	anti-VACV	antibodies.	The	ability	of	soluble	HShi	(A)	and	HSlow	(B)	(10	μg/mL)	to	inhibit	MV	binding	to	immobilised	heparin	is	presented.	Dashed	lines	indicate	background	binding	of	MV	to	BSA	coated	wells.	Control	bars	represent	MV	binding	to	immobilised	heparin	in	the	absence	of	soluble	HShi	or	HSlow.		Data	presented	as	mean	±	SEM	(n=8)	and	representative	of	three	independent	experiments.	Statistical	analysis	was	performed	using one-way ANOVA with Dunnett’s multiple comparisons. *** - p < 
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Proteins	identified	 Accession	#:	 Score†	 Sequences	matched*	
DNA	directed	RNA	polymerase	132	kDa	peptide	(Cowpox	virus)	 NP_619941.1	 1436	 26	DNA	directed	RNA	polymerase	147	kDa	peptide	(Variola	virus)	 ABG44469.1	 254	 7	DNA	directed	RNA	polymerase	147	kDa	peptide	(Vaccinia	virus)	 AAB96506.1	 223	 7	
Major	core	protein	4b	(Vaccinia	virus)	 AAA48118.1	 103	 2	
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8.1	Introduction	The	expansion	of	traditional	areas	of	habitation,	along	with	mass	long-distance	travel,	has	opened	up	the	possibility	of	rapid	widespread	dissemination	of	new	and	re-emerging	pathogens	once	considered	eradicated	and	is	regarded	as	a	major	concern	for	the	medical	and	public	health	systems	worldwide	(Littler	&	Oberg,	2005;	Morens	et	al.,	2004).	Moreover,	the	threat	of	eradicated	viruses	like	smallpox	being	used	as	potential	weapons	of	bioterrorism	has	attracted	a	lot	of	interest	in	the	scientific	community	and	has	stimulated	the	fast-track	development	of	novel	antiviral	treatments	(Hughes	et	al.,	2010).	With	this	increasing	disease	burden	on	the	public	health	system,	increasing	efforts	are	being	made	by	the	scientific	community	to	understand	viral	pathogenesis	and	develop	new	strategies	to	treat	these	infections	(Finlay	et	al.,	2004).		Research	targeted	at	understanding	the	molecular	pathways	controlling	virus	life	cycles	is	the	engine	that	drives	the	development	of	therapies	against	viral	infections	(Liang	&	Ghany,	2013).	Furthermore,	use	of	‘combination	therapies’	using	disease-modifying	treatments	acting	on	hosts,	coupled	with	inhibitors	of	virus	replication,	have	shown	great	potential	in	the	treatment	of	viral	infections	(Littler	&	Oberg,	2005).	An	example	of	combination	therapy	is	the	treatment	of	hepatitis	C	virus	(HCV)	using	inhibitors	of	HCV	proteases,	along	with	treatment	for	fibrosis,	which	could	have	a	major	impact	on	liver	disease	(Elbaz,	El-Kassas,	&	Esmat,	2015;	Littler	&	Oberg,	2005).	Another	example	is	the	treatment	of	HSV	where	the	use	of	aciclovir,	an	inhibitor	of	HSV	replication,	combined	with	an	anti-inflammatory	agent,	has	resulted	in	a	significant	decrease	in	HSV-1	infections	
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(Hull,	Levin,	Tyring,	&	Spruance,	2014;	Littler	&	Oberg,	2005;	Opstelten,	Neven,	&	Eekhof,	2008).			
8.2	VACV	interacts	with	cell	surface	HS	The	research	focus	of	this	thesis	was	the	development	of	an	understanding	of	the	molecular	mechanisms	used	by	VACV	to	enter	and	infect	cells,	particularly	the	role	of	HS,	an	understanding	that	would	be	valuable	for	the	design	of	antivirals	that	could	potentially	inhibit	VACV	infections.	VACV	is	a	member	of	the	Orthopoxvirus	(OPV)	genus	of	the	Poxviridae	family.	VACV	was	the	vaccine	strain	used	to	eradicate	smallpox,	however,	it	wasn’t	until	1939	that	scientists	realized	that	the	strain	of	poxviruses	being	used	to	vaccinate	against	smallpox	was,	in	fact,	VACV	and	not	the	cowpox	virus	(CPXV)	originally	used	by	Edward	Jenner	in	1796	(Roberts	&	Smith,	2008).	Today,	VACV	is	commonly	used	as	the	prototype	virus	to	study	poxviruses.			VACV,	like	many	other	viruses,	interacts	with	cell	surface	HS	prior	to	interacting	with	specific	cell	surface	receptors	that	mediate	its	entry	into	cells	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	ELISA	results	presented	in	Chapter	3	of	this	thesis	clearly	suggest	that	the	MV	form	of	VACV	binds	to	immobilised	HShi,	with	only	soluble	heparin	being	a	potent	inhibitor	of	this	binding,	suggesting	that	the	MV	form	of	VACV	preferentially	interacts	with	GAG	molecules	with	extremely	high	sulfate	content	(Figures	3.1	and	3.2).	The	MV	form	of	VACV	also	has	a	known	CS	binding	protein	on	its	outer	membrane	(Hsiao	et	al.,	1999),	however,	the	unavailability	of	BSA	conjugated	CS	meant	similar	ELISA	studies	could	not	be	performed	to	determine	the	strength	of	interaction	between	MV	particles	and	immobilised	CS.	
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Nevertheless,	an	alternative	ELISA	assay	was	designed	to	determine	if	soluble	CS	could	inhibit	MV	particles	from	binding	to	immobilised	HShi	in	ELISA	wells.	Only	very	high	concentrations	of	CS	could	partially	inhibit	MV	binding,	suggesting	that	soluble	CS	could	indirectly	interfere	with	the	interaction	between	immobilised	HShi	and	proteins	on	the	MV	outer	membrane	(Figure	3.4).	Furthermore,	there	is	ample	published	evidence	indicating	that	soluble	CS	has	little	effect	on	MV	infectivity	(Carter	et	al.,	2005),	therefore,	it	would	be	safe	to	conclude	that	the	GAG	molecule	that	plays	a	major	role	in	VACV	infectivity	is	cell	surface	HS	(and	soluble	heparin,	a	highly	sulfated	version	of	HS).		Previously	published	studies	have	shown	that	there	are	at	least	two	HS-binding	proteins	on	the	outer	membrane	of	MV	particles,	however,	due	to	the	fragile	nature	of	the	outer	EV	envelope,	similar	studies	using	the	EV	form	of	VACV	have	not	been	undertaken	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	Nevertheless,	plaque	assay	results	presented	in	Figure	3.5	clearly	demonstrate	that	heparin/HS	play	a	crucial	role	in	the	way	VACV	forms	plaques	on	cell	monolayers	in	vitro.	Not	only	does	the	presence	of	heparin	in	the	culture	medium	reduce	the	plaque	numbers	of	the	WR	and	IHD-J	strains	of	VACV	by	5-	to	10-fold,	but	it	also	influences	the	plaque	morphology	(Figure	3.5).	Thus,	there	was	an	incremental	increase	in	the	diameter	of	WR	strain	plaques	(MV	rich	strain	of	VACV)	in	the	presence	of	heparin.	However,	the	effect	of	heparin	on	IHD-J	strain	plaques	(EV	rich	strain	of	VACV)	was	more	dramatic,	with	the	disappearance	of	the	trademark	‘comets’	associated	with	EV	plaques	and	a	similar	incremental	increase	in	plaque	diameter	as	seen	with	the	WR	strain.		
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Previously	published	studies	have	shown	that	the	VACV	A56	protein,	also	known	as	the	VACV	haemagglutinin	(HA),	binds	to	and	forms	a	complex	with	a	serine	protease	inhibitor	(K2)	(DeHaven	et	al.,	2011;	Moss,	2006).	Infected	cells	express	A56/K2	complexes	on	their	plasma	membranes,	which	interact	with	the	entry/fusion	complex	(EFC)	on	the	membrane	of	new	MV	particles	and	inhibit	the	ability	of	the	EFC	to	mediate	MV	entry	into	cells	(DeHaven	et	al.,	2011;	Turner	&	Moyer,	2008).	The	EFC	is	composed	of	at	least	eight	proteins,	namely,	A16,	A21,	A28,	G3,	G9,	H2,	J5	and	L5	(Wagenaar	&	Moss,	2009).	The	interaction	of	the	A56/K2	complex	with	the	EFC	on	the	surface	of	MV	particles	is	a	mechanism	in	place	to	avoid	superinfection	of	infected	cell,	resulting	in	MV	particles	only	being	able	to	infect	cells	that	do	not	have	the	A56/K2	complex	expressed	on	their	surface	(Turner	&	Moyer,	2008).	Antibodies	against	the	A56	or	K2	proteins	have	been	shown	to	decrease	the	interaction	of	the	A56/K2	complex	with	EFC	on	MV	and,	therefore,	increase	the	amount	of	superinfection	(DeHaven	et	al.,	2011).	Furtheremore,	the	A56/K2	complex	has	been	shown	to	inhibit	syncytia	formation	(Moss,	2006)	and	infected	cells	are	able	to	fuse	with	uninfected	cells	at	neutral	pH	when	mutant	viruses	lacking	A56	or	K2	are	used	to	infect	cells	(Turner	&	Moyer,	2008).	There	is	also	evidence	that	suggests	that	K2	contains	a	heparin-binding	site	similar	to	that	of	antithrombin	III	(Brum	et	al.,	2003;	Turner	&	Moyer,	2006).	Furthermore,	Western	blotting	results	presented	in	Figure	6.2B	clearly	indicate	that	the	A56	protein	binds	to	heparin-Sepharose	beads.	Therefore,	to	put	the	plaque	assay	results	presented	in	Figure	3.5	in	perspective,	a	possible	reason	for	the	increased	plaque	diameter	is	that	the	A56/K2	complexes	expressed	on	the	plasma	membrane	of	infected	cells	could	be	blocked	by	heparin,	similar	to	the	effects	seen	when	an	antibody	against	A56	or	K2	is	used,	which	then	permits	
		 208	
syncytia	formation.	This	would	mean	that	plaque	size	would	grow	at	a	faster	rate	in	the	presence	of	heparin.	Apart	from	interacting	with	the	A56/K2	complex,	heparin	also	directly	inhibits	EV	and	MV	forms	of	VACV	from	interacting	with	cell	surface	HS,	which	would	explain	the	5-	10-fold	reduction	in	plaque	numbers	observed.			Unlike	MV	particles,	which	are	generally	released	from	dying	cells,	EV	particles	are	actively	ejected	from	infected	cells	(Figure	1.4),	a	process	that	results	in	the	infection	of	distal	cells	and	the	formation	of	the	trademark	‘comet’	shaped	plaques.	However,	in	the	presence	of	heparin,	the	comets	formed	by	the	IHD-J	strain	of	VACV	almost	completely	disappeared	(Figure	3.5A	and	B).	It	is	likely	that	heparin	inhibits	freshly	released	EV	particles	from	infecting	neighbouring	cells	as	heparin	is	a	potent	inhibitor	of	EV	infections	in	vitro	as	measured	by	the	infections	using	GFP	expressing	EV	form	of	VACV	(Chapters	4	and	5)	and	by	the	IHD-J	strain	(EV	rich)	plaque	formation	(Figure	3.5).	Furthermore,	newly	formed	MV	particles	in	an	infected	cell	can	directly	be	pushed	into	neighbouring	cells	and	escape	interaction	with	heparin	(Marsh	&	Helenius,	2006).	Therefore,	it	is	likely	that	in	the	presence	of	heparin,	the	predominant	mode	of	spread	of	the	IHD-J	strain	of	VACV	is	via	the	punching	mechanism	used	by	MV	particles.	This	would	also	explain	why	the	IHD-J	strain	of	VACV	forms	round	plaques	in	the	presence	of	heparin.			
8.3	EV	and	MV	forms	of	VACV	interact	differently	with	cell	surface	HS		The	plaque	assay	results	presented	in	Figure	3.5	clearly	show	that	heparin	affects	the	EV	rich	strain	of	VACV	(IHD-J)	differently	to	the	MV	rich	strain	(WR).	
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Therefore,	it	was	important	to	evaluate	the	role	of	heparin/HS	in	infections	caused	by	the	EV	and	MV	forms	of	VACV.			The	outer	most	envelope	of	the	EV	form	of	VACV	is	extremely	fragile	(Ichihashi,	1996).	This	makes	purification	of	the	EV	form	extremely	challenging	because	an	EV	particle	with	a	damaged	outer	membrane	behaves	like	an	MV	particle	(see	Figure	3.5F	showing	broken	outer	EV	envelope).	Therefore,	to	understand	the	interaction	between	EV	particles	and	cell	surface	HS,	it	was	first	essential	to	design	protocols	to	obtain	relatively	concentrated	stocks	of	EV.	Since	the	IHD-J	strain	of	VACV	is	constitutively	rich	in	the	amount	of	EV	particles	it	sheds	compared	to	the	WR	strain	of	VACV,	the	IHD-J	strain	was	used	to	obtain	EV	stocks	for	the	assays	performed	in	this	thesis.	The	WR	strain	of	VACV	was	used	to	obtain	MV	stocks.			In	order	to	understand	the	interaction	between	cell	surface	HS	and	VACV	during	an	infection,	GFP	expressing	recombinants	of	both	the	WR	and	IHD-J	strains	of	VACV	were	created.	The	kinetics	of	EV-GFP	and	MV-GFP	infection	were	monitored	by	measuring	GFP	expression	in	cells	at	different	time-points	post	infection.	Co-incubation	of	heparin	with	either	EV-GFP	or	MV-GFP	during	the	infection	of	cell	monolayers	revealed	that	heparin	was	a	much	more	potent	inhibitor	of	EV	infections	than	MV	infections	(Figures	4.3	and	4.7).	Since	the	EV	and	MV	forms	of	VACV	used	in	these	infection	assays	were	purified	from	two	different	strains	of	VACV,	it	was	important	to	rule	out	the	possibility	that	strain	differences	were	the	cause	of	the	differences	seen	in	EV	and	MV	infectivity.	It	was	found,	however,	that	the	EV	particles	isolated	from	the	WR	strain	of	VACV	could	be	inhibited	by	heparin	to	a	similar	extent	as	EV	particles	isolated	from	the	IHD-J	strain	(Figure	4.7).	
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Similarly,	MV	particles	isolated	from	the	IHD-J	strain	of	VACV	showed	comparable	inhibition	by	heparin	to	MV	particles	isolated	from	the	WR	strain	of	VACV	(Figure	4.7).	These	observations	clearly	suggest	that	EV	particles,	regardless	of	their	source,	are	more	susceptible	to	inhibition	by	heparin	than	MV	particles.	The	tightly	overlapping	inhibition	curves	observed	in	these	experiments	also	highlight	the	reproducibility	of	the	inhibition	assay	used.		
8.4	Role	of	heparanase	in	VACV	spread	Heparanase	is	the	only	known	mammalian	endoglycosidase	that	is	able	to	cleave	HS	in	ECM	and	BMs,	therefore,	it	was	of	interest	to	understand	the	effect	of	heparanase-mediated	digestion	of	HS	on	EV	and	MV	infectivity	in	vitro.	Digestion	of	cell	surface	HS	using	platelet	derived	HPSE	or	commercially	available	
Flavobacterium	HPNSEs,	significantly	reduced	EV	and	MV	infectivity,	however,	the	reduction	in	infectivity	was	more	severe	for	the	EV	particles	than	the	MV	particles	(Figure	4.5).	Since	HPSE	and	HPNSE	digestion	of	cell	surface	HS	is	incomplete,	the	digestions	probably	leaving	HS	stubs	on	cell	monolayers,	this	could	explain	why	a	complete	inhibition	of	the	EV	and	MV	infections	was	not	observed.	Nevertheless,	it	was	evident	that	EV	infections	are	more	dependent	on	the	presence	of	cell	surface	HS	than	MV	infections.	Furthermore,	infection	assays	performed	with	a	cell	line	genetically	deficient	in	the	production	of	HS	confirmed	the	previous	finding	that	EV	infections	are	significantly	affected	by	the	unavailability	of	cell	surface	HS	(Figure	4.6),	whereas	the	MV	form	is	much	less	dependent	on	HS	to	infect	cells.	Since	the	EV	form	of	VACV	is	responsible	for	long-range	dissemination	in	vivo	(Ichihashi,	1996)	and	the	knowledge	that	heparanase	is	the	only	known	mammalian	endoglycosidase	that	mediates	extracellular	HS	degradation	in	vivo	
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(Levy-Adam	et	al.,	2010;	Parish	et	al.,	2001),	it	was	of	interest	to	determine	the	ability	of	VACV	to	spread	in	mice	deficient	in	heparanase	expression.			To	perform	in	vivo	spreading	assays,	it	was	essential	to	consider	the	route	of	inoculation	of	VACV.	Traditionally	used	routes	for	infection	assays,	such	as	intraperitoneal	or	intravenous	inoculation,	allow	the	systemic	spread	of	VACV	particles,	which	is	essential	to	study	immune	responses	against	VACV	infections.	However,	since	the	research	question	in	this	thesis	was	to	understand	VACV	spread	to	different	organs,	it	was	important	to	deliver	VACV	at	restrictive	sites	in	order	to	cause	VACV	particles	to	first	establish	an	infection	at	the	primary	site	of	inoculation,	before	spreading	to	distant	organs.	Both	i.m.	and	i.n.	routes	of	delivery	where	thus	used	to	perform	the	in	vivo	assays.			Results	presented	in	Chapter	7	clearly	suggest	that	there	is	a	definite	delay	in	disease	onset	in	HPSE-/-	mice	inoculated	with	the	WR	strain	of	VACV	by	both	the	i.n.	and	i.m.	routes,	compared	to	WT	C57BL/6	control	mice.	Plaque	assays	performed	on	organs	harvested	from	both	the	HPSE-/-	and	WT	mice	infected	with	the	WR	strain	of	VACV	clearly	demonstrated	that	VACV	was	able	to	establish	an	infection	at	the	primary	site	of	inoculation	with	comparable	efficiency	in	both	animal	groups,	however,	VACV	dissemination	to	ovaries,	a	distal	organ,	was	delayed	in	the	HPSE-/-	mice	compared	to	the	WT	mice.	Since	the	EV	form	of	VACV	is	mainly	responsible	for	the	long-range	dissemination	of	the	virus,	it	is	likely	that	the	lack	of	heparanase	in	the	HPSE-/-	mice	had	its	greatest	effect	on	the	dissemination	of	progeny	EV	particles.	The	in	vitro	results	presented	in	Chapter	4	showing	that	EV	particles,	but	not	MV	particles,	much	less	efficiently	infect	
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heparanase	treated	cell	monolayers,	is	consistent	with	the	spread	of	the	EV	form	of	VACV	being	highly	heparanase	dependent.	In	fact,	it	could	be	argued	that	the	existence	of	two	forms	of	VACV,	namely	the	EV	and	MV	forms,	with	substantially	different	affinities	for	HS,	provides	the	virus	with	a	diversity	of	spreading	mechanisms	that	could	be	advantageous.			There	is	a	large	body	of	evidence	indicating	that	several	viruses,	bacteria	and	parasites	use	evolutionary	conserved	glycosaminoglycans,	including	HS,	as	adhesion	receptors	during	their	infection	of	cells	(Rostand	&	Esko,	1997;	Wadstrom	&	Ljungh,	1999).	However,	based	on	the	data	presented	in	this	thesis,	it	is	highly	likely	that	such	pathogens	are	dependent	on	heparanase,	usually	host	derived,	for	their	dissemination	from	their	initial	site	of	infection.	In	fact,	a	recent	publication	reported	that	the	spread	of	HSV-1	is	heparanase	dependent	(Hadigal	et	al.,	2015).	Of	considerable	interest	is	whether	viruses,	such	as	HSV-1,	produce	progeny	virus	particles	with	variability	in	their	affinity	for	HS	as	is	the	case	with	VACV.	It	should	be	noted,	however,	that	heparanase	deficiency	delays	but	does	not	totally	prevent	virus	spread.	The	heterogeneity	in	HS	binding	affinity	of	viruses	could	partially	explain	this	observation.	An	additional	possibility	is	that	proteases	that	degrade	ECM	and	BMs	could	also	aid	the	spread	of	HS	binding	viruses	(Levy-Adam	et	al.,	2010).		
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8.5	Chemically	modified	heparins	and	HS	mimetics	can	inhibit	VACV	
infections	Having	established	that	cell	surface	HS	is	important	for	the	infection	of	cells	by	both	the	EV	and	MV	forms	of	VACV,	but	particularly	the	EV	form,	combined	with	the	ability	of	soluble	heparin	to	interfere	with	EV	and	MV	infections,	it	was	important	to	delineate	the	structural	features	of	heparin/HS	that	influence	the	infectivity	of	the	EV	and	MV	forms	of	VACV.		Initial	inhibition	assays	performed	using	Fondaparinux,	along	with	other	commercially	available	LMWHs,	suggested	that	these	compounds	are	just	as	potent	as	heparin	in	their	ability	to	inhibit	EV	and	MV	infections	(Figure	5.1).	Since	Fondaparinux	and	other	LMWHs	contain	the	antithrombin	III	binding	pentasaccharide	of	heparin,	which	allows	them	to	be	antithrombotic,	it	is	likely	that	the	EV	and	MV	particles	also	interact	with	the	same	pentasaccharide	sequence.	Similar	to	heparin,	EV	infections	are	more	susceptible	to	inhibition	by	Fondaparinux	and	other	LMWHs,	compared	to	MV	infections.	However,	based	on	these	results,	it	is	likely	that	antithrombotic	drugs	may	be	able	to	act	as	antivirals	by	interfering	with	the	interaction	of	EV	and	MV	particles	of	VACV	with	cell	surface	HS.	These	results,	along	with	previously	published	results,	raise	the	notion	of	a	so	called	‘sulfation	code’,	which	entails	sulfated	sequences	along	the	length	of	HS	chains	that	permits	high	avidity	binding	to	certain	proteins	or	VACV,	as	seen	in	the	current	study	(Lindahl	&	Kjellen,	2013).		Previously	published	studies	showing	inhibition	assays	performed	using	HSV,	which	also	interacts	with	cell	surface	HS	prior	to	infecting	cells,	revealed	that	2,3-
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O-sulfate	and	6-O-sulfate	groups	are	critical	for	heparin	to	interact	with	the	gB	and	gC	glycoproteins	on	the	surface	of	HSV-1	(Feyzi	et	al.,	1997;	Trybala	et	al.,	2000).	Results	presented	in	Chapter	4	indicate	that	highly	sulfated	HS	(HShi)	inhibits	VACV	infections	much	more	efficiently	than	under-sulfated	HS	(HSlow).	Previously	published	HSV	infection	studies,	together	with	the	finding	reported	in	this	thesis	that	key	sulfate	groups	on	free	heparin/HS	chains	can	inhibit	VACV	infections,	suggest	that	cell	surface	HS	can	act	as	an	important	co-receptor	for	VACV	infections.	However,	to	validate	the	‘sulfation	code’	hypothesis,	a	series	of	inhibition	assays	were	performed	to	extensively	analyze	key	structural	features	of	heparin/HS	to	which	VACV	particles	bind.	Structural	analyses	using	chemically	modified	heparins	revealed	that	the	2-O-sulfate	groups	of	the	iduronic/glucuronic	acid	residues	are	not	important	for	the	ability	of	heparin	to	inhibit	EV	and	MV	infections.	However,	6-O-sulfate	and	N-sulfate	groups	of	the	D-glucosamine	residues	are	crucial	for	the	ability	of	heparin	to	inhibit	VACV	infections	(Figure	5.2).		Furthermore,	neither	N-acetylation	of	glucosamine	residues,	nor	the	removal	of	carboxyl	groups	from	the	iduronic/glucuronic	acid	residues,	had	any	effect	on	the	ability	of	heparin	to	inhibit	EV	and	MV	infections	(Figure	5.3).	These	results,	therefore,	validate	the	‘sulfation	code’	hypothesis	in	the	context	of	VACV	infections.			In	addition	to	using	chemically	modified	heparins,	sulfated	di-	and	oligo-saccharides	that	differ	in	their	sulfation	patterns,	monosaccharide	constituents	and	linkages	were	examined	in	Chapter	5	for	their	anti-VACV	activity,	these	molecules	being	termed	HS	mimetics.	Data	obtained	from	these	studies	indicate	that	the	linkage	of	different	D-glucose-based	sulfated	saccharides	plays	a	crucial	role	in	the	ability	of	the	molecules	to	inhibit	VACV	infections,	with	the	order	of	
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potency	being	β(1g4)	>	α(1g6)	>	α(1g4)	>	β(1g3),	with	sulfated	pentasaccharides	being	usually	the	most	effective.	These	results	add	a	layer	of	complexity	suggesting	that	the	position	of	negatively	charged	sulfated	groups	in	3D	space	determines	the	antiviral	activity	of	these	molecules	and,	therefore,	builds	on	the	notion	of	a	‘sulfation	code’.		
8.6	Anti-cancer	drug	PI-88	(Muparfostat)	can	inhibit	VACV	infections	The	anti-cancer	drug	PI-88	inhibits	heparanase-mediated	degradation	of	HS,	thereby	inhibiting	tumour	metastasis	and	reducing	tumour	growth	by	inhibiting	angiogenesis	(Khachigian	&	Parish,	2004).	PI-88	is	currently	in	a	Phase	III	trial	as	a	monotherapy	in	post-resection	hepatocellular	carcinoma	patients.	Since	PI-88	is	a	mixture	of	highly	sulfated	oligosaccharides,	it	was	of	interest	to	determine	if	PI-88	can	act	as	an	inhibitor	of	VACV	infections.	Indeed	PI-88	could	inhibit	both	EV	and	MV	infections,	however,	it	was	surprising	to	note	that	of	all	the	inhibitors	tested	in	the	assays	presented	in	this	thesis,	PI-88	was	the	only	molecule	that	was	a	more	potent	inhibitor	of	MV	infections	than	of	EV	infections.	PI-88	does	differ	from	other	HS	mimetics	as	PI-88	is	based	on	the	monosaccharide	D-mannose,	whereas	the	other	HS	mimetics	described	in	Chapter	5	as	inhibitors	of	VACV	are	D-glucose-based	saccharides.	Furthermore,	PI-88	is	composed	of	α(1g3)	and	α(1g2)	linked	D-mannose	residues	(Yu	et	al.,	2002),	which	also	differs	from	the	linkages	of	the	D-glucose-based	HS	mimetics	examined.	These	data	are	again	consistent	with	the	notion	that	the	ability	of	HS-based	saccharide	molecules	to	inhibit	VACV	infectivity	is	dependent	on	the	position	of	the	negatively	charged	groups	of	the	inhibitor	in	3D	space.			
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PI-88	has	also	been	shown	to	have	a	significant	effect	on	the	disease	outcome	in	dengue	virus	and	flaviviral	encephalitis	mouse	models	(Lee	et	al.,	2006).	Therefore,	based	on	the	results	presented	in	this	thesis,	mixtures	of	heparin-/HS-based	molecules,	an	excellent	example	being	a	mixture	of	PI-88	and	Fondaparinux	that	are	drugs	already	used	clinically,	would	likely	be	effective	antiviral	agents	against	VACV	as	each	saccharide	molecule	targets	different	VACV	forms.			
8.7	EV	surface	proteins	that	interact	with	HS/heparin	The	MV	form	of	VACV	has	two	known	HS-binding	proteins	on	its	outer	membrane	(Chung	et	al.,	1998;	Lin	et	al.,	2000).	Studies	published	by	Law	et	al.,	2006,	suggest	that	the	EV	outer	membrane	proteins	A34R	(24-28	kDa)	and	B5R	(42	kDa)	interact	with	cell	surface	HS,	which	results	in	lysis	of	the	outer	EV	envelope	to	release	the	enclosed	MV	particles	(Law	et	al.,	2006).	However,	results	presented	in	this	thesis	clearly	suggest	that	soluble	heparin,	LMWHs,	certain	chemically	modified	heparins	and	HS-based	oligosaccharides,	are	able	to	inhibit	EV-mediated	infectivity	with	higher	affinity	than	the	MV-mediated	infectivity.	Therefore,	it	was	important	to	determine	whether	any	other	protein(s)	on	the	surface	of	EV	interact	with	heparin/HS.			Bioinformatic	searches	were	performed	to	identify,	based	on	sequence	homology	using	known	HS-binding	protein,	the	outer	EV	membrane	proteins	that	would	interact	with	cell	surface	HS.	The	EV	membrane	proteins	were	also	solublised,	co-incubated	with	heparin-coupled	beads,	and	identified	via	Western	blotting	using	VACV-specific	antibodies.	A	150	kDa	protein	band	observed	on	blots	was	excised	and	sent	to	APAF	for	identification	by	mass	spectrometry	(MS)	analysis.	The	MS	
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analysis	identified	the	150	kDa	band	as	the	147	kDa	DNA	directed	RNA	polymerase	with	a	sequence	similarity	to	65	kDa	VACV	F12,	a	protein	involved	in	the	export	of	newly	formed	MV	particles.		Interestingly,	Western	blotting	also	identified	a	~60	kDa	heparin	binding	protein,	however,	due	to	time	constrains,	the	~60	kDa	band	could	not	be	sent	for	MS	analysis.	Nevertheless,	the	VACV	F12	protein	could	be	a	candidate	for	the	unknown	~60	kDa	protein	identified	via	Western	blotting.	Furthermore,	the	bioinformatics	searches	identified	a	65	kDa	VACV	B4R	protein	that	is	an	important	protein	responsible	for	effective	plaque	formation.	Therefore,	VACV	B4R	could	also	be	a	candidate	protein	for	the	unknown	~60	kDa	protein.		Western	blotting	also	identified	an	85	kDa	heparin-binding	protein,	which	was	a	different	protein	to	VACV	HA	(A56R).	Bioinformatic	searches	identified	a	77.6	kDa	RNA	helicase	that	had	a	possible	heparin-binding	motif.		Therefore,	it	is	possible	that	the	77.6	kDa	RNA	helicase	is	the	~85	kDa	unknown	protein	(Figure	6.2A).	Similar	to	B4R,	an	RNA	helicase-specific	mAb	would	be	required	to	conclusively	identify	the	~85	kDa	protein.	Furthermore,	MS	analysis	could	be	performed	to	identify	the	unknown	protein.	Lastly,	a	25	kDa	heparin-binding	protein	was	also	observed	in	blots,	however,	the	identity	of	this	protein	is	unknown	although	it	could	be	the	previously	described	24-28	kDa	A34R	protein	on	the	EV	surface	that	binds	heparin	(Law	et	al.,	2006).	MS	analysis	would	be	required	to	conclusively	identify	all	the	unknown	proteins.		Assays	performed	using	heparin/HS	mimetics	clearly	support	the	notion	of	the	‘sulfation	code’	in	3D	space.	Therefore,	it	is	likely	that	there	are	protein(s)	on	the	surface	of	the	EV	envelope,	other	than	A34R	and	B5R,	that	based	on	bioinformatics	
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analysis	are	not	obvious	HS-binding	proteins	but	when	folded	in	their	tertiary	orientation	are	able	to	interact	with	HS.	As	an	example,	human	papillomavirus	type	16	has	multiple	HS-binding	proteins	on	its	capsid,	with	the	interaction	between	primary	HS-binding	sites	and	HS	inducing	a	conformational	change	that	exposes	secondary	HS-binding	sites,	which	are	then	able	to	interact	with	cell	surface	HS	(Richards	et	al.,	2013).		
8.8	Conclusion	and	future	directions	To	summarize,	it	is	clear	that	VACV,	like	several	other	viruses,	interacts	with	cell	surface	HS	to	infect	cells.	However,	as	described	in	a	recently	published	study	on	HSV-1,	it	is	likely	that	VACV	also	relies	on	heparanase-mediated	degradation	of	HS	in	order	to	spread	to	distal	sites	in	vivo.	Nevertheless,	HS-based	molecules	could	potentially	be	used	to	inhibit	VACV	infections.	In	fact,	extensive	studies	of	different	HS	mimetics	outlined	in	this	thesis	suggest	that	synthetic	HS-based	molecules	could	be	synthesized	that	target	both	EV	and	MV	forms	of	VACV.	Furthermore,	many	of	the	HS	mimetics	with	antiviral	activity	may	also	act,	like	PI-88,	as	heparanase	inhibitors	and	consequently	inhibit	virus	spread.		A	number	of	important	unanswered	questions	arise	from	the	data	presented	in	this	thesis.	First,	what	are	the	key	heparin/HS	binding	molecules	on	the	surface	of	the	MV	and	EV	forms	of	VACV.	Western	blotting	studies	have	identified	several	VACV	proteins,	based	on	molecular	weight,	that	bind	heparin/HS.	MS	studies	need	to	be	undertaken	to	identify	these	molecules,	similar	to	the	approach	used	to	identify	the	150	kDa	VACV	protein	binding	to	heparin-Sepharose	beads	in	Chapter	6.	Whether	the	newly	identified	heparin/HS	binding	proteins	simply	aid	adhesion	
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of	VACV	to	cells,	activate	EV	envelope	disintegration	or	prevent	superinfection	of	cells	by	VACV	also	needs	to	be	investigated.	Second,	although	heparanase	has	been	clearly	shown	to	aid	VACV	spread,	the	source	of	the	host-derived	heparanase	is	unknown.	An	obvious	source	is	host	leukocytes	entering	sites	of	infection,	particularly	neutrophils	and	macrophages.	Platelets	are	another	source	of	heparanase	as	the	platelets	carry	large	amounts	of	preformed	heparanase	that	is	rapidly	released	following	platelet	activation	(Freeman	&	Parish,	1998),	a	likely	scenario	for	cytopathic	viruses	such	as	VACV.	Thrombocytopenic	mice,	such	as	the	
c-mpl	knockout	mice	(Murone,	Carpenter,	&	de	Sauvage,	1998),	or	platelet	depleting	mAbs	could	be	used	to	establish	whether	VACV	spread	is	platelet	dependent.	If	this	is	the	case,	use	of	mice	in	which	platelet	heparanase	is	conditionally	knocked	out	would	conclusively	demonstrate	that	platelet-derived	heparanase	aids	VACV	spread.	Conversely,	if	platelets	are	not	involved,	the	conditional	knocking	out	of	heparanase	in	myeloid	cells	could	be	used	to	establish	the	leukocyte	origin	of	heparanase.			Finally,	it	will	be	of	considerable	interest	whether	other	pathogens	that	use	HS	as	a	co-receptor	for	infecting	cells	behave	in	a	similar	manner	as	VACV.	In	particular,	do	they	use	host	heparanase	to	aid	pathogen	spread	and	do	they	produce	pathogen	variants	with	different	HS	binding	properties?	Such	questions,	when	answered,	may	reveal	new	approaches	to	controlling	the	spread	of	numerous	pathogens.	
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